NCT02197455

Tofacitnib for the Treatment of Alopecia Areata and Variants

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Detailed description

This study is an open-label pilot study. Participants will be treated with oral tofacitinib for a maximum of 5 months. Participants will be evaluated at 3 months after completion of therapy to evaluate for durability of response, late response and/or late adverse effects.

Conditions

• Alopecia Areata (AA)
• Alopecia Totalis (AT)
• Alopecia Universalis (AU)

Interventions

Type	Name	Description
DRUG	Tofacitinib Administration	5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.

Timeline

• Start date: 2014-07-01
• Primary completion: 2015-07-01
• Completion: 2015-07-01
• First posted: 2014-07-22
• Last updated: 2017-04-04
• Results posted: 2017-04-04

Locations

1 site across 1 country: United States